Cargando…
Fatal case of sorafenib-associated idiosyncratic hepatotoxicity in the adjuvant treatment of a patient with renal cell carcinoma
BACKGROUND: Sorafenib is an orally available kinase inhibitor with activity at Raf, PDGFβ and VEGF receptors that is licensed for the treatment of advanced renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC). Current evidence-based post-nephrectomy management of individuals with localized...
Autores principales: | Fairfax, BP, Pratap, S, Roberts, ISD, Collier, J, Kaplan, R, Meade, AM, Ritchie, AW, Eisen, T, Macaulay, VM, Protheroe, A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3575366/ https://www.ncbi.nlm.nih.gov/pubmed/23231599 http://dx.doi.org/10.1186/1471-2407-12-590 |
Ejemplares similares
-
Identification of a metabolic biomarker panel in rats for prediction of acute and idiosyncratic hepatotoxicity
por: Sun, Jinchun, et al.
Publicado: (2014) -
Investigation of the idiosyncratic hepatotoxicity of Polygonum multiflorum Thunb. through metabolomics using GC-MS
por: Lin, Yan, et al.
Publicado: (2021) -
Mechanistic Understanding of Idiosyncratic Drug-Induced Hepatotoxicity Using Co-Cultures of Hepatocytes and Macrophages
por: Villanueva-Badenas, Estela, et al.
Publicado: (2023) -
Comparison of TNFα to Lipopolysaccharide as an Inflammagen to Characterize the Idiosyncratic Hepatotoxicity Potential of Drugs: Trovafloxacin as an Example
por: Liguori, Michael J., et al.
Publicado: (2010) -
What Survival Benefits are Needed to Make Adjuvant Sorafenib Worthwhile After Resection of Intermediate- or High-Risk Renal Cell Carcinoma? Clinical Investigators’ Preferences in the SORCE Trial
por: Lawrence, Nicola J., et al.
Publicado: (2018)